Access to anti-retroviral drugs, female in Mali

Mali: Access to anti-retroviral drugs, female was 73.0% in 2024. ◆ Volatile

Latest (2024)
73.0%
Change on year
up 7.4%
World rank
71st
of 141 countries
All-time high
73.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Mali, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 1 %2004: 3 %2005: 3 %2006: 8 %2007: 12 %2008: 16 %2009: 19 %2010: 22 %2011: 30 %2012: 29 %2013: 30 %2014: 32 %2015: 35 %2016: 37 %2017: 41 %2018: 45 %2019: 45 %2020: 54 %2021: 52 %2022: 58 %2023: 68 %2024: 73 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Mali stood at 73.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 7.4% on the previous year and up 128.1% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Mali peaked at 73.0% in 2024 and was at its lowest, 0.0%, in 2000.

Mali ranks 71st of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Mali, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Mali, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 1.0%
2004 3.0% +200.0%
2005 3.0% +0.0%
2006 8.0% +166.7%
2007 12.0% +50.0%
2008 16.0% +33.3%
2009 19.0% +18.8%
2010 22.0% +15.8%
2011 30.0% +36.4%
2012 29.0% -3.3%
2013 30.0% +3.4%
2014 32.0% +6.7%
2015 35.0% +9.4%
2016 37.0% +5.7%
2017 41.0% +10.8%
2018 45.0% +9.8%
2019 45.0% +0.0%
2020 54.0% +20.0%
2021 52.0% -3.7%
2022 58.0% +11.5%
2023 68.0% +17.2%
2024 73.0% +7.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 6.2% 0.0% 19.0% 10
2010s 34.6% 22.0% 45.0% 10
2020s 61.0% 52.0% 73.0% 5

Countries ranked near Mali

  1. 69 Comoros 74.0% compare
  2. 69 El Salvador 74.0% compare
  3. 71 Bahrain 73.0% compare
  4. 71 Central African Republic 73.0% compare
  5. 71 Guatemala 73.0% compare
  6. 71 Sri Lanka 73.0% compare

See the full ranking of 160 places →

More gender data for Mali

All data for Mali →

Frequently asked questions

What is access to anti-retroviral drugs, female in Mali?
Access to anti-retroviral drugs, female in Mali was 73.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Mali?
The highest recorded value was 73.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Mali?
The lowest recorded value was 0.0% in 2000.
How does Mali rank for access to anti-retroviral drugs, female?
Mali ranks 71st out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Mali?
Over the last ten years it is up 128.1%. The long-run trend across the full record is volatile.
Where does this Mali data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Mali. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/mali/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/mali/">Access to anti-retroviral drugs, female in Mali</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.